Mark Sheptoff Financial Planning LLC Has $91,000 Position in DaVita Inc. (NYSE:DVA)

Mark Sheptoff Financial Planning LLC boosted its stake in DaVita Inc. (NYSE:DVA) by 64.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 657 shares of the company’s stock after purchasing an additional 257 shares during the quarter. Mark Sheptoff Financial Planning LLC’s holdings in DaVita were worth $91,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. 8 Knots Management LLC bought a new position in shares of DaVita in the 4th quarter worth $89,504,000. Doma Perpetual Capital Management LLC bought a new stake in DaVita during the fourth quarter worth $53,076,000. Harvard Management Co. Inc. bought a new position in DaVita in the 2nd quarter valued at $55,115,000. Norges Bank purchased a new stake in shares of DaVita during the 4th quarter valued at $36,626,000. Finally, Allianz Asset Management GmbH raised its stake in shares of DaVita by 63.9% during the 4th quarter. Allianz Asset Management GmbH now owns 548,642 shares of the company’s stock worth $57,476,000 after purchasing an additional 213,992 shares during the period. 90.12% of the stock is owned by institutional investors.

Insider Buying and Selling

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the transaction, the insider now directly owns 83,011 shares in the company, valued at approximately $12,137,038.31. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, COO Michael David Staffieri sold 9,539 shares of DaVita stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the completion of the sale, the chief operating officer now directly owns 241,945 shares of the company’s stock, valued at approximately $36,299,008.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the transaction, the insider now directly owns 83,011 shares in the company, valued at approximately $12,137,038.31. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 173,482 shares of company stock worth $27,387,069. Corporate insiders own 2.00% of the company’s stock.

DaVita Trading Down 0.6 %

Shares of DVA opened at $163.16 on Thursday. The business’s 50-day moving average price is $146.25 and its 200-day moving average price is $140.54. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94. DaVita Inc. has a twelve month low of $71.51 and a twelve month high of $166.04. The stock has a market cap of $14.31 billion, a PE ratio of 18.54, a P/E/G ratio of 0.95 and a beta of 0.87.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, August 6th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.47 by $0.12. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The business had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.15 billion. During the same quarter in the prior year, the firm posted $2.08 EPS. DaVita’s revenue was up 6.2% on a year-over-year basis. On average, equities analysts forecast that DaVita Inc. will post 9.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Truist Financial increased their price objective on DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a report on Tuesday, August 20th. TD Cowen lifted their price objective on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. Bank of America upped their price objective on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a report on Wednesday, August 7th. StockNews.com downgraded shares of DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. Finally, UBS Group upped their price target on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, DaVita has a consensus rating of “Hold” and an average target price of $157.00.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.